Hematologic Malignancies Demystified - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Hematologic Malignancies Demystified

A Critical Appraisal of Data from 2018

Not a member of My prIME? Join now for instant access.

Explore the options in benign hematology and hematologic malignancies with these downloadable slides. Expert faculty examine updates from recent congresses and present the latest clinically relevant data.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Mar 14, 2019

Expiration Date

Mar 14, 2020

Featured Expert

  • Richard M. Stone, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

Acute leukemia

Featured Expert

  • Guillermo Garcia-Manero, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Myelodysplastic syndromes

Featured Expert

  • Srdan Verstovsek, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Myeloproliferative neoplasms

Featured Expert

  • Jorge Cortes, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

Featured Topic

Chronic myelogenous leukemia

Featured Expert

  • Barbara Pro, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States

Featured Topic

Hodgkin lymphoma

Featured Expert

  • Julie Vose, MD, MBA, University of Nebraska Medical Center, Omaha, Nebraska, United States

Featured Topic

Non-Hodgkin lymphoma

Featured Expert

  • Susan O'Brien, MD, UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange, California, United States

Featured Topic

Chronic lymphocytic leukemia

Featured Expert

  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Featured Topic

Multiple myeloma

Featured Expert

  • Sergio Giralt, MD, FACP, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Featured Topic

Complications of transplant

Featured Expert

  • Stephan Moll, MD, University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States

Featured Topic

Benign hematology

This educational activity is specifically designed for practicing medical oncologists, hematologists, registered nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in and/or involved in the treatment of patients with cancer in the United States.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Analyze emerging data from clinical trials investigating established and novel treatment options
  • Distinguish the adverse event profiles of different options for hematologic malignancies and strategies to manage these side effects
  • Evaluate expert recommendations for patient selection and sequencing, biomarker use, and monitoring treatment response

Nurses

  • Analyze emerging data from clinical trials investigating established and novel treatment options
  • Identify the most common side effects associated with treatment of hematologic malignancies and appropriate strategies for prevention, recognition, and management of these events
  • Evaluate the clinical evidence supporting the utilization of cytogenetic markers, minimal residual disease and other prognostic/predictive tests, and counsel patients on their role

This educational activity is supported by grants from AbbVie Inc.; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Celgene Corporation; Gilead Sciences, Inc.; Jazz Pharmaceuticals; Novartis Oncology; and Seattle Genetics, Inc.

Enduring Material From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by The University of Texas MD Anderson Cancer Center  and prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by The University of Texas MD Anderson Cancer Center and prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center and prIME Oncology assess relevant financial relationships with their instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by The University of Texas MD Anderson Cancer Center and prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. The University of Texas MD Anderson Cancer Center and prIME Oncology are committed to providing their learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

For All Meetings

Dr Cortes discloses that he has received grants or research support from Bristol-Myers Squibb, Novartis, Pfizer, Sun Pharma, and Takeda. He also discloses paid consulting for Bristol-Myers Squibb, Novartis, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Garcia-Manero discloses that he has received grants or research support from AbbVie, Amphivena, Astex, Celgene, H3 Bio, Helsinn, Merck, Novartis, and Onconova. He also discloses paid consulting for Amphivena, Astex, and Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Giralt discloses that he has received grants or research support from Actinium, Amgen, Celgene, Johnson & Johnson, Miltenyi, Sanofi, and Takeda. He also discloses that he has received honoraria from Actinium, Amgen, Celgene, Johnson & Johnson, Kite, Novartis, Sanofi, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lonial discloses that he has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Novartis, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moll discloses paid consulting for and receipt of honoraria from Janssen and Portola Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Brien discloses that she has received consulting fees from AbbVie; Alexion; Amgen; Aptose Biosciences, Inc.; Astellas; Celgene; Gilead; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis; TG Therapeutics; and Vaniam Group LLC. She has also received research support from Acerta, Gilead, Kite, Pfizer, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Pro discloses grants or research support from and paid consulting for Seattle Genetics and Takeda. She also discloses grants or research support from Celgene. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Stone discloses that he has received consulting fees from AbbVie, Agios, Amgen, Arog, Astellas, AstraZeneca, Celgene, Cornerstone, Fujifilm, Jazz, Macrogenics, Novartis, Orsenix, Otsuka/Astex, Pfizer, and Sumitomo. He also discloses receipt of research funding from Agios, Arog, and Novartis. He discloses scientific advisory board participation for Actinium. He has served on a steering committee for Celgene and on the data safety monitoring boards for Argenx, Celgene, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Verstovsek discloses that he has received research support from AstraZeneca, Blueprint Medicines Corporation, Bristol-Myers Squibb, Celgene, CTI BioPharma Corporation, Galena BioPharma, Genentech, Gilead, Incyte Corporation, Lilly Oncology, Ns Pharma, Pfizer, Promedior, Roche, and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vose discloses research grant support from Amgen; Acerta Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Kite Pharma; Merck; Novartis; and Seattle Genetics, Inc. She also discloses consulting/honorarium from AbbVie, Acerta/AstraZeneca, Epizyme, Janssen/Pharmacyclics, Kite Pharma, Kyopharm, Legend Pharmaceuticals, Nordic Nanovector, Novartis, Roche, Sandoz, Vaniam Group, and Verastem. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Brooke Balun (lead nurse planner) – no relevant financial relationships
  • Briana Betz, PhD (scientific content reviewer/planner) – worked on IME projects supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis Oncology, Pfizer, and TG Therapeutics
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

The employees of MD Anderson have disclosed:

  • Tamara C. Greiner, MA, CHCP – no relevant financial relationships.

The CME reviewers/approvers have disclosed:

  • Dan Gombos, MD – paid consultant:  AbbVie; other relevant financial or material interests:  Aura biosciences, 3T Biosciences
  • Kyle Jones, PhD – no relevant relationships
  • Brian Weston, MD – no relevant relationships
  • Diane C. Bodurka, MD, MPH – no relevant relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.